CA-CLICKHOUSE
Today, ClickHouse, Inc, creators of the online analytical processing (OLAP) database management system, announced the general availability of their newest offering, ClickHouse Cloud, a lightning-fast cloud-based database that simplifies and accelerates insights and analytics for modern digital enterprises. With no infrastructure to manage, ClickHouse Cloud architecture decouples storage and compute and scales automatically to accommodate modern workloads, so users do not have to size and tune their clusters to achieve blazing-fast query speeds. This launch includes a host of new product features, enhancing the security, reliability and usability of ClickHouse Cloud.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221206005590/en/
ClickHouse Cloud SQL console (Graphic: Business Wire)
ClickHouse technology allows a company to turn their data into insights and innovation in near real-time, whether it's a bank trying to detect fraud or a streaming service tracking the next blockbuster. With every modern business relying on massive volumes of data, the ability to derive insights in milliseconds from petabytes of data becomes critically important. The launch of ClickHouse Cloud, available at both www.clickhouse.com and through the AWS Marketplace, allows any company to access this technology on demand for the first time.
ClickHouse Cloud is production-ready with a host of new features, including SOC 2 Type II compliance and uptime SLAs for production workloads, with a public trust center and status page that provide reassurance to customers building mission-critical data-based apps on the service. Following the successful acquisition of database client Arctype, users will benefit from a new SQL console that will enable them to connect, explore, and query their databases easily.
“The advantage of ClickHouse is speed and simplicity, and ClickHouse Cloud takes that to a new level, enabling businesses to start a service and analyze data a fraction of the cost of other solutions on the market,” said Aaron Katz, CEO of ClickHouse. “In just a few months, the ClickHouse Cloud beta has gained over 100 customers and thousands of new users spanning across developers, data analysts, marketing and other critical areas of business where data is analyzed and stored.”
"ClickHouse Cloud aligns with our desire to empower our developers to go from concept to delivery on real-time analytics use cases in days, speeding up the product innovation cycle drastically. We are thrilled to collaborate with ClickHouse Cloud when it comes to performance, scalability, and security,” says Eyal Manor, Chief Product Officer of Twilio.
Over 100 paying customers have already adopted ClickHouse Cloud during the two-month beta phase, and are experiencing the ability to focus on developing business-critical data applications without the burden of operations resources.
In addition, the serverless, production-ready ClickHouse Cloud offering adds a tier optimized for development use cases. This is tuned for smaller workloads and recognizes the importance of lower-cost services enabling rapid prototyping of new features and data products. A user can now architect, model, and experiment with ClickHouse Cloud in preparation for a full production deployment.
Alongside these fundamental product announcements, ClickHouse is delighted to further validate its market opportunity, team, and business model following fresh investment from leading technology investor Thrive Capital, as an extension to its Series B. This funding will support further investment in technology and allow ClickHouse to continue building its world-leading team of software engineers.
“ClickHouse offers the most efficient database for fast and large-scale analytics,” said Avery KIemmer, an investor at Thrive Capital. “We have long admired this team and are excited to partner with them as they launch ClickHouse Cloud to an even wider audience.”
About ClickHouse
ClickHouse is the world's fastest and most resource-efficient online analytical column-oriented database management system. Now offered as a secure and scalable serverless offering in the cloud, ClickHouse Cloud allows anyone to effortlessly take advantage of efficient real-time analytical processing. Learn more at clickhouse.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221206005590/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
ImmunAbs Announces FDA Phase 2 IND Approval of IM-101, a Novel Complement C5 Inhibitor, for Treatment of Myasthenia Gravis2.6.2025 13:00:00 CEST | Press release
ImmunAbs Inc., a clinical-stage biotech specializing in developing antibody therapeutics, today announced that the U.S. Food and Drug Administration has cleared its Investigational New Drug (IND) application to initiate a Phase 2 clinical trial evaluating the safety and efficacy of IM-101, a novel complement C5 inhibitor, for the treatment of Myasthenia Gravis. The forthcoming multicenter, randomized, double-blind, placebo-controlled study will enroll up to 90 patients to evaluate the effectiveness and safety of monthly IM-101 dosing in relieving complement-induced symptoms in MG. “This IND approval is pivotal for us as it brings us one step closer to delivering a transformative therapy for patients with autoimmune disorders”, said Dr. Dongjo Kim, the CEO of ImmunAbs, “we believe IM-101 has the potential to deliver deeper therapeutic responses and more durable remissions in patients who have failed to achieve sustained remission with current approved treatment.” About Myasthenia Gravis
Lenovo and Bellevue University Team Up to Offer Supply Chain and Logistics Education to Deliver “Smarter Technology for All”2.6.2025 13:00:00 CEST | Press release
Learners will have access to Lenovo’s globally recognized supply chain expertise through real-world case studies and subject matter experts. Lenovo, the global technology powerhouse, recognized in the top 10 in the Gartner Supply Chain Top 25, and Bellevue University, one of the nation’s top online universities, are teaming up to develop the next generation of supply chain professionals. “We believe that bringing real-world Global Supply Chain experience and learning directly into an education curriculum is precisely the optimal way to upskill the workforce of the future,” said Ben Massie, Vice President, Global Supply Chain, Lenovo. “Teaming up with Bellevue allows us to attract the right talent using the right technology and deliver on our mission to make ‘smarter technology for all’ a reality.” As a preferred higher education institution tapped to team up with Lenovo to offer supply chain short-term learning, Bellevue will leverage the breadth and depth of Lenovo’s supply chain expe
Lifezone Metals Files Initial Assessment for the Kabanga Nickel Project in Tanzania2.6.2025 12:30:00 CEST | Press release
Vertically Integrated Plan includes Hydrometallurgical Refinery at Kahama $2.37 Billion After-Tax NPV (8%) and 22.9% After-Tax IRR at $8.49 per Pound Nickel Price Initial Assessment Proposes a 22-Year Mine Plan at Average 2.39% Nickel Equivalent Grade Webcast with Technical Leadership Team at 10 AM ET on Tuesday, June 3, 2025 Lifezone Metals Limited’s (NYSE: LZM) Chief Executive Officer, Chris Showalter, and Chief Operating Officer, Gerick Mouton, announce today the results from the Initial Assessment for its flagship Kabanga Nickel Project in northwest Tanzania. The Initial Assessment evaluates a vertically integrated mining, processing and refining operation, commencing with a high-grade nickel sulfide underground mine and concentrator at the Kabanga site, followed five years later by a hydrometallurgical refinery at Kahama. The study covers the Main, MNB, Kima, North, and Tembo zones and is based on the December 2024 Mineral Resource Update (refer to Lifezone’s December 5, 2024 news
Corpay Cross-Border Named an Official Partner of Real Madrid C.F.2.6.2025 12:00:00 CEST | Press release
Providing access to currency risk management and cross-border payments solutions Corpay, Inc.*, (NYSE: CPAY) a global leader in corporate payments, is pleased to announce that Corpay’s Cross-Border business has entered into an agreement with Real Madrid C.F. to become an Official Partner. Through this partnership, Real Madrid will be able to gain access to and utilise Corpay Cross Border’s innovative solutions to help mitigate foreign exchange exposure from their day-to-day business needs. "The Corpay Cross-Border team is elated to be named an Official Partner of Real Madrid, one of the world’s most widely recognized and followed sports franchises," said Brad Loder, Chief Marketing Officer, Corpay Cross-Border Solutions. “With our strong focus on growing the Corpay brand, as well as our currency risk management business, we are excited to partner with one of the most successful football clubs in the world.” About Corpay Corpay, Inc. (NYSE: CPAY) is a global S&P500 corporate payments co
BeOne Medicines Unveils Promising Clinical Data for Two Novel Breast Cancer Therapies at ASCO 20252.6.2025 12:00:00 CEST | Press release
Preliminary results highlight anti-tumor activity and favorable safety profiles of both B7-H4-targeting ADC and CDK2 inhibitorData underscore strength of emerging breast cancer pipeline as part of BeOne’s global transformation with next wave of innovation BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, announced new clinical data from its emerging breast cancer pipeline at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago. Poster presentations feature preliminary results of the dose escalation studies of two investigational molecules: BG-C9074, a novel B7-H4-targeting antibody-drug conjugate (ADC) in patients with advanced solid tumors, including breast cancer, and BG-68501, a cyclin-dependent kinase-2 inhibitor (CDK2i), in HR+/HER2- breast cancer patients with prior CDK4/6i exposure. “Presenting the first clinical data for two novel breast cancer candidates at ASCO 2025 marks a pivotal moment for BeOne,” said Mark Lanas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom